The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. Tirzepatide injection has been in shortage since 2022 due to increased demand.
Similar Posts
Zingerman’s Candy Manufactory Issues Allergy Alert on Undeclared Peanut & Cashew in Candy Bars
Zingerman’s Candy Manufactory of Ann Arbor, Michigan is recalling Zingerman’s Peanut Butter Crush Full Size Bars with Lot#174250 because it may contain undeclared cashew and Zingerman’s Ca$hew Cow Full Size Bars with Lot#174250 because it may contain undeclared peanut. People who have an allergy orFDASIA Section 705 Annual Reports
Annual Reports published by requirement of FDASIA Section 705Aspirin for Reducing Your Risk of Heart Attack and Stroke: Know the Facts
Information on using aspirin daily, over-the-counter, with other medicines, as well as its side effectsLiquidCapsule Manufacturing, LLC – 717069 – 12/19/2025
CGMP/Finished Pharmaceuticals/AdulteratedGeneric Competition and Drug Prices
FDA report demonstrating greater competition among generic drug makers can lead to lower generic drug prices.PureRawz – 715218 – 09/08/2025
Unapproved New Drugs/Misbranded